Literature DB >> 7549064

Plasminogen activators and plasminogen activator inhibitors: biochemical aspects.

D C Rijken1.   

Abstract

Although this chapter does not represent a historical review, it will be clear how the biochemistry of t-PA, u-PA, PAI-1 and PAI-2 has evolved and where we stand in 1994. While the functional activities of the proteins were recognized at least three to four decades ago, highly purified preparations became available around 1980. In the mid-eighties the cDNAs of the proteins were cloned, representing a major breakthrough in the biochemistry of the four proteins. Amino acid sequences were derived from the nucleotide sequences, homologies with other proteins were recognized and larger amounts of (recombinant) proteins became available for research. In addition, mutant proteins were prepared by recombinant DNA technology, enabling investigation of structure-function relationships. This report is mainly based on the latter studies. Detailed information about three-dimensional structures of the proteins and the mode of interaction with other macromolecules is still lacking. To obtain this information will be the goal for biochemists in the coming years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7549064     DOI: 10.1016/s0950-3536(05)80269-0

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  14 in total

1.  Three-dimensional structure of fibrolase, the fibrinolytic enzyme from southern copperhead venom, modeled from the X-ray structure of adamalysin II and atrolysin C.

Authors:  M B Bolger; S Swenson; F S Markland
Journal:  AAPS PharmSci       Date:  2001

2.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

3.  A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation.

Authors:  S Selvarajan; L R Lund; T Takeuchi; C S Craik; Z Werb
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

4.  Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.

Authors:  M Osmak; I Vrhovec; J Skrk
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

Review 5.  Lifestyle, fibrinolysis and lipids.

Authors:  E J Brommer; J A Gevers Leuven; P Brakman
Journal:  Pharm World Sci       Date:  1997-04

Review 6.  Advances in diabetes for the millennium: diabetes and the endothelium.

Authors:  Paresh Dandona; Ahmad Aljada
Journal:  MedGenMed       Date:  2004-09-29

7.  Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.

Authors:  Manolis C Demetriou; Michael E Pennington; Raymond B Nagle; Anne E Cress
Journal:  Exp Cell Res       Date:  2004-04-01       Impact factor: 3.905

8.  Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex.

Authors:  Pia Lindberg; Anita Billström; Bertil Kinnby
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 9.  Bleeding Disorders in Primary Fibrinolysis.

Authors:  Massimo Franchini; Marco Zaffanello; Pier Mannuccio Mannucci
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 10.  Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination.

Authors:  Sarbani Bhattacharya; Victoria A Ploplis; Francis J Castellino
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.